Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  methylprednisolone
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 36 for your search:
Start Over
Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: seromprotocol, NCT00307606
Unrelated Double Umbilical Cord Blood Units Transplantation
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 50
Sponsor: Other
Protocol IDs: HORCSCT-0902, NCT01015742
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: CDR0000686545, 2009-012758-18, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: ANHL1131, NCI-2012-01963, CDR0000732604, IGR2009/1593, 2010-019224-31, U10CA098543, U10CA180886, COG-ANHL1131, NCT01595048
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: JSPH-CLL-001, NCT01670812
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2012-0501, NCI-2013-01666, NCT01875237
A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 140396, NCT02229422
Evaluation Study of Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory HL
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BRESHAP-GELTAMO.LH-2013, 2014-000835-17, NCT02243436
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: LR-ESHAP, NCT02340936
ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 20
Sponsor: Other
Protocol IDs: IMACEL, NCT02431403
a Phase II Study in Primary Central Nervous System Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: T1406, NCT00455286
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 05-0303-04, P30CA023074, CDR0000597508, HSC#0567, UARIZ-SRC17899, UARIZ-HSC-0567, 05-0303-01, NCT00732498
Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Phase: Phase II
Type: Treatment
Status: Active
Age: 75 and under
Sponsor: Other
Protocol IDs: CDR0000600351, AMC-UUCM-2008-0038, 2008-0038, NCT00731328
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 75
Sponsor: Other
Protocol IDs: CDR0000659891, AMC-UUCM-2009-0579, 2009-0579, NCT01020734
Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: Allo-039, NCT01252784
R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LMTG 11-01, NCT01278602
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: NCCCTS-10-524, NCT01300156
Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Other
Protocol IDs: 2010-0981, NCI-2011-02767, NCT01409161
Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0030, NCI-2011-02941, NCT01424982
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-304, NCCN Protocol Number: NCCN-001, GSK Protocol Number: OFT115580, NCT01465334
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16622, GSK OFT114879, RV-CLL-PI-0560, NCT01496976
Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CARMEN, NCT01516593
Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18 less than 80
Sponsor: Other
Protocol IDs: ICLL01 BOMP, NCT01612988
Horse ATG in Patients With AA or Low/Int-1 Risk MDS
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2012-0334, NCI-2012-01096, NCT01624805
Start Over